Table 1 Peer-reviewed publications included in the scoping study
Primary authors | Ethical issues emphasized | Setting | Method* |
|---|---|---|---|
Bärnighausen T, Salomon JA, Sangrujee N: HIV Treatment as Prevention: Issues in Economic Evaluation. PLoS Med 2012, 9:e1001263. | A, B, C | Worldwide | Commentary |
Bärnighausen T, Tanser F, Dabis F, Newell M-L: Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa. Current Opinion in HIV and AIDS 2012, 7: 140–150. | C | Sub-Saharan Africa | Rapid Review |
Barr D, Amon JJ, Clayton M: Articulating a rights-based approach to HIV treatment and prevention interventions. Current HIV research 2011, 9: 396–404. | A, B | Worldwide | Commentary |
Chan R: Biomedical Strategies for Human Immunodeficiency Virus (HIV) Prevention? A New Paradigm. Ann Acad Med Singapore 2012, 41: 595–601. | A, B, C | Worldwide | Review |
Chang LW, Serwadda D, Quinn TC, Wawer MJ: Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis 2013, 13:65–76. | C | Sub-Saharan Africa | Review |
Chen Y: Treatment-Related Optimistic Beliefs and Risk of HIV Transmission: A Review of Recent Findings (2009–2012) in an Era of Treatment as Prevention. Curr HIV/AIDS Rep 2012, 10: 79–88. | C | Worldwide | Review |
Cohen T, Corbett EL: Test and treat in HIV: success could depend on rapid detection. The Lancet 2011, 378: 204–206. | A, B, C | Sub-Saharan Africa | Commentary |
Dawson L: The Devil in the Details: Thorough Assessment of Evidence and Ethics Is Needed in Evaluating New HIV Prevention Methods. Am J Bioethics 2012, 12: 33–34. | A, C | Worldwide | Commentary |
Dennin RH, Lafrenz M, Sinn A, Li L: Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights. J Zhejiang U 2011, 12: 591–610. | A | Worldwide | Commentary |
Forsyth AD, Valdiserri RO: Reaping the prevention benefits of highly active antiretroviral treatment. Current Opinion in HIV and AIDS 2012, 7: 111–116. | A, B, C | Worldwide | Commentary |
Garnett GP, Baggaley RF: Treating our way out of the HIV pandemic: could we, would we, should we? The Lancet 2009, 373: 9–11. | A, C | Worldwide | Commentary |
Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sonnerborg A, Nachega JB: Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. J Infect Dis 2013, 207: S101–S106. | C | International | Commentary |
Haire BG: Because we can: clashes of perspective over researcher obligation in the failed PrEP trials. Dev world bioethics 2011, 11: 63–74. | A, B, C | Worldwide | Commentary |
Haire BG, Kaldor J, Jordens CFC: How good is “good enough”? The case for varying standards of evidence according to need for new interventions in HIV prevention. Am J Bioethics 2012, 12: 21–30. | A, B, C | Worldwide | Commentary |
Krellenstein J, Strub, S: The ethical implications of “treatment as prevention” in the United States. 2012, 16:1–4. | A, C | United States | Commentary |
Kulkarni SP, Shah KR, Sarma KV, Mahajan AP: Clinical Uncertainties, Health Service Challenges, and Ethical Complexities of HIV “Test-and-Treat”: A Systematic Review. Am J Public Health 2013, 103: e14–e23. | A, B, C | Worldwide | Systematic Review |
Macklin R, Cowan E: Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Health Aff 2012, 31:1537–1544. | A, B | United States | Commentary |
McNairy ML, Cohen M, El-Sadr WM: Antiretroviral Therapy for Prevention Is a Combination Strategy. Curr HIV/AIDS Rep 2013, 10: 152–8. | B, C | Worldwide | Commentary |
McNairy ML, Howard AA, El-Sadr WM: Antiretroviral Therapy for Prevention of HIV and Tuberculosis: A Promising Intervention but Not a Panacea. JAIDS 2013, 63: S200–7. | B, C | Worldwide | Commentary |
Mayer KH: Antiretrovirals for HIV prevention: translating promise into praxis. The Lancet 2011, 378:206–208. | B, C | Sub-Saharan Africa | Commentary |
Montaner JS: Treatment as prevention: a double hat-trick. The Lancet 2011, 378:208–209. | C | Canada | Commentary |
Nguyen V-K, Bajos N, Dubois-Arber F, O’Malley J, Pirkle CM: Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention. AIDS 2011, 25:291–293. | A, C | Worldwide | Commentary |
Ostmann F, Saenz C: Separate Goals, Converging Priorities: On the Ethics of Treatment as Prevention. Developing World Bioethics 2013, 13:57–62. | A, B | Worldwide | Commentary |
Singh JA: Antiretroviral resource allocation for HIV prevention. AIDS 2013, 27:863–865. | B, C | Worldwide | Commentary |
Small W, Kerr T: HIV Treatment as Prevention and the Role of Applied Social Science Research. Journal of AIDS & Clinical Research 2013, 02:102e. | B, C | Worldwide | Commentary |
Cates W: HPTN 052 and the future of HIV treatment and prevention. The Lancet 2011, 378: 224–5. | A, B, C | Worldwide | Correspondence |
Lancet Infectious Diseases: Editorial: Treatment as prevention for HIV. The Lancet Infect Dis 2011, 11:651. | B, C | Worldwide | Commentary |
Vonn M: British Columbia’s ‘seek and treat’ strategy: a cautionary tale on privacy rights and informed consent for HIV testing. HIV/AIDS Policy & Law Review 2012, 16:1–4. | A, C | Canada | Commentary |
Williams B, Wood R, Dukay V, Delva W, Ginsburg D, Hargrove J, Stander M, Sheneberger R, Montaner J, Welte A: Treatment as prevention: preparing the way. JIAS 2011, 14:S6. | A, B, C | Worldwide | Commentary |